Utility of a US Food and Drug Administration (FDA) label indication for condoms for anal sex

被引：1

作者：

Siegler, Aaron J. ^{[1
]}

Ahlschlager, Lauren ^{[1
]}

Rosenthal, Elizabeth M. ^{[2
,3
]}

Sullivan, Patrick S. ^{[2
]}

Kelley, Colleen F. ^{[4
]}

Rosenberg, Eli S. ^{[2
,3
]}

Sanchez, Travis H. ^{[2
]}

Moore, Renee H. ^{[5
]}

Mehta, C. Christina ^{[5
]}

Cecil, Michael P. ^{[6
]}

机构：

[1] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA

[2] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA

[3] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, One Univ Pl, Rensselaer, NY 12144 USA

[4] Emory Univ, Sch Med, 1648 Pierce Dr NE, Atlanta, GA 30307 USA

[5] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, 1518 Clifton Rd NE, Atlanta, GA 30322 USA

[6] TheyFit LLC, 4140 Tate St NE, Covington, GA 30014 USA

来源：

SEXUAL HEALTH | 2020年 / 17卷 / 01期

基金：

美国国家卫生研究院;

关键词：

HIV; prevention; sexual and gender minorities; HIV;

D O I：

10.1071/SH18152

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Condoms are highly effective for HIV prevention, yet are not currently indicated by the US Food and Drug Administration (FDA) for anal sex. We surveyed a national sample of men who have sex with men to assess whether FDA label indication could affect anticipated condom use, and to determine levels of perceived condom failure for anal sex. We found that 69% of respondents anticipated that a label indication change would increase their likelihood of condom use. Median perceived failure was 15%. We anticipate that these results may aid the FDA in developing standards for a label indication for anal sex.

引用

页码：91 / 95

页数：5

共 50 条

[21] Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment''
Savage, Kevin T.
Flood, Kelsey S.
Popatia, Sabrina
Golbari, Nicole M.
Salian, Prerna
Kimball, Alexa B.
Porter, Martina L.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : E19 - E20
[22] Promotion of Drugs for Off-label Uses The US Food and Drug Administration at a Crossroads
Kim, Jeanie
Kapczynski, Amy
[J]. JAMA INTERNAL MEDICINE, 2017, 177 (02) : 157 - 158
[23] Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA)
Weaver, Joyce
La Grenade, Lois
Kwon, Hyon
Avigan, Mark
[J]. DERMATOLOGIC THERAPY, 2009, 22 (03) : 204 - 215
[24] US Food and Drug Administration Updates
Sahin, L.
[J]. BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 748 - 748
[25] Transparency at the US Food and Drug Administration
Califf, Robert M.
[J]. JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 24 - 28
[26] Independence at the US Food and Drug Administration
不详
[J]. LANCET, 2006, 367 (9523): : 1630 - 1630
[27] Urokinase and the US food and drug administration
Ouriel, K
[J]. JOURNAL OF VASCULAR SURGERY, 1999, 30 (05) : 957 - 958
[28] Introduction to the food and drug administration (FDA) regulatory process
Hackett, JL
Gutman, SI
[J]. JOURNAL OF PROTEOME RESEARCH, 2005, 4 (04) : 1110 - 1113
[29] Medical device evaluation by the food and drug administration (FDA)
Nelson, DB
Block, KP
Bosco, JJ
Burdick, JS
Curtis, WD
Faigel, DO
Greenwald, DA
Kelsey, PB
Rajan, E
Slivka, A
Smith, P
VanDam, J
Wassef, W
Wang, KK
[J]. GASTROINTESTINAL ENDOSCOPY, 2001, 53 (07) : 880 - 884
[30] Food and Drug Administration FDA is gold standard of review
Leahey, Mark B.
[J]. BRITISH MEDICAL JOURNAL, 2010, 341

← 1 2 3 4 5 →